140 related articles for article (PubMed ID: 35615381)
21. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
22. Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy.
Wang Z; Li X; Wang X; Liu J; Wang L; Wei W; Duan X; Ding D
J Immunol Res; 2022; 2022():6737241. PubMed ID: 35677536
[TBL] [Abstract][Full Text] [Related]
23. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
[No Abstract] [Full Text] [Related]
24. Identification and validation of novel biomarkers affecting bladder cancer immunotherapy
Wang J; He X; Bai Y; Du G; Cai M
Front Immunol; 2022; 13():1051063. PubMed ID: 36439109
[TBL] [Abstract][Full Text] [Related]
25. Risk score based on three mRNA expression predicts the survival of bladder cancer.
Liu Q; Diao R; Feng G; Mu X; Li A
Oncotarget; 2017 Sep; 8(37):61583-61591. PubMed ID: 28977887
[TBL] [Abstract][Full Text] [Related]
26. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Cell Int; 2020; 20():276. PubMed ID: 32607061
[TBL] [Abstract][Full Text] [Related]
27. An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.
Zhang F; Feng D; Wang X; Gu Y; Shen Z; Yang Y; Wang J; Zhong Q; Li D; Hu H; Han P
Front Mol Biosci; 2021; 8():780329. PubMed ID: 35004850
[No Abstract] [Full Text] [Related]
28. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
Gao X; Cai J
Front Genet; 2022; 13():865204. PubMed ID: 35571063
[No Abstract] [Full Text] [Related]
29. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
30. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
31. Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer.
Zheng Z; Mao S; Zhang W; Liu J; Li C; Wang R; Yao X
Front Oncol; 2020; 10():542492. PubMed ID: 33392066
[TBL] [Abstract][Full Text] [Related]
32. Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer.
Zhang F; Wang X; Bai Y; Hu H; Yang Y; Wang J; Tang Y; Ma H; Feng D; Li D; Han P
Front Genet; 2021; 12():670384. PubMed ID: 34122523
[TBL] [Abstract][Full Text] [Related]
33. Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer.
Zheng H; Luo W; Li Y; Peng G; Zhou D; Tang D; Cheng J; Wu S
Front Cell Dev Biol; 2022; 10():837849. PubMed ID: 35309900
[No Abstract] [Full Text] [Related]
34. A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.
Zheng X; Zhou X; Xu H; Jin D; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Genet; 2021; 12():764184. PubMed ID: 34899849
[TBL] [Abstract][Full Text] [Related]
35. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
36. Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer.
Song X; Xin S; Zhang Y; Mao J; Duan C; Cui K; Chen L; Li F; Liu Z; Wang T; Liu J; Liu X; Song W
Front Cell Dev Biol; 2022; 10():810272. PubMed ID: 35265613
[TBL] [Abstract][Full Text] [Related]
37. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
38. CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and
Yu Y; Wang Y; Zou Y; Yu Y
Dis Markers; 2022; 2022():5286820. PubMed ID: 35707714
[TBL] [Abstract][Full Text] [Related]
39. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
Lu H; Wu J; Liang L; Wang X; Cai H
Front Immunol; 2022; 13():803355. PubMed ID: 35154117
[TBL] [Abstract][Full Text] [Related]
40. MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer.
Yi R; Hong S; Zhang Y; Lin A; Ying H; Zou W; Wang Q; Wei T; Cheng Q; Zhu W; Luo P; Zhang J
Front Cell Dev Biol; 2022; 10():757137. PubMed ID: 35223828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
